Cargando…
CMT1A current gene therapy approaches and promising biomarkers
Charcot-Marie-Tooth neuropathies (CMT) constitute a group of common but highly heterogeneous, non-syndromic genetic disorders affecting predominantly the peripheral nervous system. CMT type 1A (CMT1A) is the most frequent type and accounts for almost ~50% of all diagnosed CMT cases. CMT1A results fr...
Autores principales: | Stavrou, Marina, Kleopa, Kleopas A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075121/ https://www.ncbi.nlm.nih.gov/pubmed/36571339 http://dx.doi.org/10.4103/1673-5374.361538 |
Ejemplares similares
-
A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice
por: Stavrou, Marina, et al.
Publicado: (2022) -
Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy
por: Kagiava, Alexia, et al.
Publicado: (2023) -
Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies
por: Stavrou, Marina, et al.
Publicado: (2021) -
Loss of Coupling Distinguishes GJB1 Mutations Associated with CNS Manifestations of CMT1X from Those Without CNS Manifestations
por: Abrams, Charles K., et al.
Publicado: (2017) -
Aberrant Mitochondrial Dynamics and Exacerbated Response to Neuroinflammation in a Novel Mouse Model of CMT2A
por: Stavropoulos, Filippos, et al.
Publicado: (2021)